Pharming Q3 operating profit jumps 89%, narrows 2026 revenue outlook

Pharming’s Q3 revenue rose 21% to $117.6 million, operating profit increased 89% to $29.9 million, and net profit reached $22.4 million versus $7.5 million a year earlier. The company narrowed its 2026 revenue forecast to $380 million-$390 million from $375 million-$395 million and lowered its operating expense forecast to $310 million-$315 million. RUCONEST Q3 revenue rose 14% to $93.8 million, while nine-month revenue was down 3%; Joenja revenue increased 58% to $23.8 million. CEO Fabrice Chouraqui stepped down, and enrollment in the FALCON trial is now expected to finish in the first half of 2027.

Analysis

The key issue is revenue quality, not the headline growth rate. RUCONEST’s quarterly rebound includes a one-pharmacy inventory build and follows a weak nine-month comparison; normalization could make the next quarter look soft even if underlying U.S. demand is stable. Joenja’s faster growth is more strategically valuable, but international ordering contributed a temporary benefit, so paid-patient additions and persistence—not quarterly revenue alone—are the cleaner read-through. The operating-profit jump also overstates recurring improvement: grants, a better finance result, and the manufacturing impairment adjustment complicate comparisons.

Near term, CEO succession and November’s leniolisib Phase II readout create event risk; the readout could expand the opportunity set, but should not be capitalized as established revenue. Over 1–3 months, verify RUCONEST sell-through versus channel inventory, Joenja paid-patient additions, and whether lower cost guidance converts to repeatable cash generation. Over 6–18 months, execution on Joenja launches and the delayed FALCON enrollment timetable matter more than a single quarter. HAE competition from established players including Takeda and BioCryst, and newer entrants such as KalVista, limits any assumption that RUCONEST’s quarterly growth marks durable share gains.

Contrarian read: the narrowed revenue range and lower expense outlook are modestly constructive, but not a clean guidance raise; the midpoint is nearly unchanged. A knee-jerk bullish read of the earnings growth risks overlooking channel timing and non-operating support. No strong directional trade on this release alone.

Key Decisions for Investors

• Keep PHAR on a catalyst watch rather than chase the quarterly beat. Reassess after the November leniolisib Phase II data; require interpretable efficacy and safety evidence before underwriting meaningful pipeline value.
• For a 1–3 month thesis, track RUCONEST sell-through and specialty-pharmacy inventory alongside Joenja paid-patient additions. Treat a sequential revenue dip as less concerning if patient metrics hold and channel inventory normalizes; weakening patient counts would falsify the stabilization thesis.
• Do not extrapolate the adjusted operating-profit figure into a durable margin run-rate. Verify the contribution from grants, the inventory impairment, and the finance result, and monitor operating cash generation against R&D and launch spending.
• CEO succession is a governance overhang, while FALCON’s later enrollment completion pushes that catalyst out. Avoid sizing PHAR as a near-term pipeline catalyst trade until interim leadership, trial timelines, and the November readout are clearer.